| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2K | — | -71.4% |
| R&D Expense | $36.6M | — | -15.8% |
| SG&A Expense | $9.6M | — | -32.0% |
| Operating Income | -$44.3M | — | +22.8% |
| Net Income | -$24.2M | — | +53.7% |
| EPS (Basic) | -$1.10 | — | -511.1% |
| EPS (Diluted) | -$1.10 | — | -511.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $90.8M | +50.8% | -24.6% |
| Short-term Investments | $163.3M | -12.7% | -9.7% |
| Current Assets | $267.3M | +2.4% | -13.5% |
| Total Assets | $350.6M | +3.1% | -18.4% |
| Current Liabilities | $36.9M | -25.2% | -10.5% |
| Total Liabilities | $77.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$38.5M | — | +29.6% |
| Capital Expenditures | $89K | — | -63.8% |
| Investing Cash Flow | $17.4M | — | -75.0% |
| Financing Cash Flow | $51.7M | — | — |
| Free Cash Flow | -$38.6M | — | +29.8% |
| -17.5% |
| Stockholders' Equity | $273.7M | +10.3% | -18.7% |